Skip to main content
. 2020 Mar 13;25(6):1320. doi: 10.3390/molecules25061320

Figure 3.

Figure 3

EVO suppresses the expression of various oncogenic proteins involved in survival, proliferation, cell cycle, angiogenesis, and metastasis and induces caspase-3 activation leading to the appearance of cleaved poly(ADP-ribose) polymerase (PARP). (A) PC-3 (5 × 105 cells/well) and DU145 cells (5 × 105 cells/well) were treated with 5 µM EVO for the indicated times. Whole cell extracts were prepared and immunoblotted with antibodies for B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidase 9 (MMP-9). (B) PC-3 (5 × 105 cells/well) and DU145 cells (5 × 105 cells/well) were treated with 5 µM EVO for the indicated times. Whole cell extracts were prepared and immunoblotted with antibodies for cleaved caspase-3, caspase-3, cleaved PARP, and PARP. (C) PC-3 (5 × 105 cells/well) and DU145 cells (5 × 105 cells/well) were pre-treated with EVO (5 µM) for 1 h then treated with HGF (100 ng/mL) or left untreated for 36 h. Whole cell extracts were prepared and immunoblotted with antibodies for Bcl-xL, COX-2, survivin, and MMP-9. (D) PC-3 (5 × 105 cells/well) and DU145 cells (5 × 105 cells/well) were pre-treated with EVO (5 µM) for 1 h then treated with HGF (100 ng/mL) or left untreated for 36 h. Whole cell extracts were prepared and immunoblotted with antibodies for cleaved caspase-3, caspase-3, cleaved PARP, and PARP. NT and EVO (−)/HGF (−) indicate control samples treated with medium containing 0.1% DMSO.